GR3022880T3 - Surface modified nsaid nanoparticles. - Google Patents

Surface modified nsaid nanoparticles.

Info

Publication number
GR3022880T3
GR3022880T3 GR970400553T GR970400553T GR3022880T3 GR 3022880 T3 GR3022880 T3 GR 3022880T3 GR 970400553 T GR970400553 T GR 970400553T GR 970400553 T GR970400553 T GR 970400553T GR 3022880 T3 GR3022880 T3 GR 3022880T3
Authority
GR
Greece
Prior art keywords
surface modified
modified nsaid
nsaid nanoparticles
nanoparticles
maintain
Prior art date
Application number
GR970400553T
Other languages
English (en)
Inventor
Gary G Liversidge
Philip Conzentino
Kenneth Cundy
Pramod P Sarpotdar
Original Assignee
Eastman Kodak Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25407503&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GR3022880(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eastman Kodak Co filed Critical Eastman Kodak Co
Publication of GR3022880T3 publication Critical patent/GR3022880T3/el

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nanotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pigments, Carbon Blacks, Or Wood Stains (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Powder Metallurgy (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GR970400553T 1992-06-10 1997-03-21 Surface modified nsaid nanoparticles. GR3022880T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89719392A 1992-06-10 1992-06-10
PCT/US1993/005082 WO1993025190A1 (en) 1992-06-10 1993-06-01 Surface modified nsaid nanoparticles

Publications (1)

Publication Number Publication Date
GR3022880T3 true GR3022880T3 (en) 1997-06-30

Family

ID=25407503

Family Applications (1)

Application Number Title Priority Date Filing Date
GR970400553T GR3022880T3 (en) 1992-06-10 1997-03-21 Surface modified nsaid nanoparticles.

Country Status (12)

Country Link
EP (1) EP0644755B1 (el)
JP (2) JP4439590B2 (el)
AT (1) ATE150297T1 (el)
AU (1) AU677783B2 (el)
CA (1) CA2118517C (el)
DE (1) DE69309056T2 (el)
DK (1) DK0644755T3 (el)
ES (1) ES2101323T3 (el)
GR (1) GR3022880T3 (el)
HU (1) HUT70952A (el)
MX (1) MX9303452A (el)
WO (1) WO1993025190A1 (el)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5399363A (en) * 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5429824A (en) * 1992-12-15 1995-07-04 Eastman Kodak Company Use of tyloxapole as a nanoparticle stabilizer and dispersant
US5518738A (en) * 1995-02-09 1996-05-21 Nanosystem L.L.C. Nanoparticulate nsaid compositions
US5591456A (en) * 1995-02-10 1997-01-07 Nanosystems L.L.C. Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer
US5834025A (en) * 1995-09-29 1998-11-10 Nanosystems L.L.C. Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions
WO1998035666A1 (en) * 1997-02-13 1998-08-20 Nanosystems Llc Formulations of nanoparticle naproxen tablets
US6045829A (en) * 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
US6013280A (en) * 1997-10-07 2000-01-11 Fuisz Technologies Ltd. Immediate release dosage forms containing microspheres
AU9587198A (en) * 1997-10-07 1999-04-27 Fuisz Technologies Ltd. Immediate release drug delivery forms
IE980115A1 (en) * 1998-02-16 2000-02-09 Biovail Internat Ltd Solubilizing delivery systems and method of manufacture
EP1117384A1 (en) * 1998-10-01 2001-07-25 Elan Pharma International Limited Controlled release nanoparticulate compositions
US8236352B2 (en) 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
UA74539C2 (en) 1999-12-08 2006-01-16 Pharmacia Corp Crystalline polymorphous forms of celecoxib (variants), a method for the preparation thereof (variants), a pharmaceutical composition (variants)
US6316029B1 (en) * 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
MY120279A (en) 2000-05-26 2005-09-30 Pharmacia Corp Use of a celecoxib composition for fast pain relief
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US20050048126A1 (en) 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
CA2461080A1 (en) 2001-09-25 2003-04-03 Pharmacia Corporation Solid-state forms of n-(2-hydroxyacetyl)-5-(4-piperidyl)-4-(4-pyrimidinyl)-3-(4-chlorophenyl)pyrazole
US20060003012A9 (en) * 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
MXPA04002446A (es) 2001-09-26 2004-07-23 Baxter Int Preparacion de nanoparticulas de tamano de submicras mediante dispersion y remocion de la fase liquida o solvente.
US9101540B2 (en) 2002-04-12 2015-08-11 Alkermes Pharma Ireland Limited Nanoparticulate megestrol formulations
JP4831965B2 (ja) * 2002-06-10 2011-12-07 エラン ファーマ インターナショナル，リミティド ＨＭＧ−ＣｏＡ還元酵素インヒビター誘導体（「スタチン」）を含むナノ粒子製剤、その新規組合せ、ならびにこれらの医薬組成物の製造
UY27939A1 (es) 2002-08-21 2004-03-31 Glaxo Group Ltd Compuestos
AU2003297260A1 (en) * 2002-11-12 2004-06-03 Elan Pharma International Ltd. Fast-disintegrating solid dosage forms being not friable and comprising pullulan
US8512727B2 (en) * 2003-03-03 2013-08-20 Alkermes Pharma Ireland Limited Nanoparticulate meloxicam formulations
US20100297252A1 (en) 2003-03-03 2010-11-25 Elan Pharma International Ltd. Nanoparticulate meloxicam formulations
EP1938803A3 (en) * 2003-03-03 2010-10-27 Elan Pharma International Limited Formulations comprising nanoparticulate meloxican
GB0418791D0 (en) 2004-08-23 2004-09-22 Glaxo Group Ltd Novel process
US9149433B2 (en) * 2004-11-30 2015-10-06 Basf Corporation Method for formation of micro-prilled polymers
KR20080047509A (ko) * 2005-05-23 2008-05-29 엘란 파마 인터내셔널 리미티드 혈소판 응집 억제제를 함유하는 나노입자형 조절 방출조성물
CL2007002689A1 (es) 2006-09-18 2008-04-18 Vitae Pharmaceuticals Inc Compuestos derivados de piperidin-1-carboxamida, inhibidores de la renina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension, insuficiencia cardiaca, fibrosis cardiaca, entre otras.
US8426467B2 (en) 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
US8722736B2 (en) 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
EP2172193A1 (en) 2008-10-02 2010-04-07 Capsulution Nanoscience AG Improved nanoparticulate compositions of poorly soluble compounds
US7828996B1 (en) 2009-03-27 2010-11-09 Abbott Cardiovascular Systems Inc. Method for the manufacture of stable, nano-sized particles
AR077692A1 (es) 2009-08-06 2011-09-14 Vitae Pharmaceuticals Inc Sales de 2-((r)-(3-clorofenil) ((r)-1-((s) -2-(metilamino)-3-((r)-tetrahidro-2h-piran-3-il) propilcarbamoil) piperidin -3-il) metoxi) etilcarbamato de metilo
JP5499703B2 (ja) * 2009-12-28 2014-05-21 ライオン株式会社 イブプロフェン含有製剤
RS56023B1 (sr) 2011-07-22 2017-09-29 Chemocentryx Inc Kristalni oblik natrijumove soli 4-terc-butil-n-[4-hlor-2-(1-okso-piridin-4-karbonil)-fenil]-benzensulfonamida
CA2842753A1 (en) 2011-07-22 2013-01-31 Chemocentryx, Inc. Polymorphic forms of the sodium salt of 4-tert-butyl-n-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide
KR20190075172A (ko) 2011-09-01 2019-06-28 글락소 그룹 리미티드 신규한 결정 형태
KR101794032B1 (ko) * 2011-09-21 2017-11-07 (주)바이오시네틱스 나노입자 제조방법
US9393202B2 (en) * 2013-04-26 2016-07-19 Chiesi Farmaceutici S.P.A Particle size reduction of an antimuscarinic compound
KR102493854B1 (ko) 2014-06-25 2023-01-30 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 (s)-6-((1-아세틸피페리딘-4-일)아미노)-n-(3-(3,4-디히드로이소퀴놀린-2(1h)-일)-2-히드록시프로필)피리미딘-4-카르복스아미드의 결정질 염
CA2960451A1 (en) 2014-09-08 2016-03-17 Glaxosmithkline Intellectual Property Development Limited Crystalline forms of 2-(4-(4-ethoxy-6-oxo-1,6-dihydropyridin-3-yl)-2-fluorophenyl)-n-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)acetamide
WO2016086950A1 (en) 2014-12-03 2016-06-09 Rontis Hellas S.A. Pharmaceutical composition containing non-lipophilic hydrophobic drug and process for the preparation thereof
JPWO2016098785A1 (ja) 2014-12-15 2017-09-21 エム・テクニック株式会社 有機物微粒子の製造方法及び有機物微粒子の改質方法
EP3528792A1 (en) 2016-10-20 2019-08-28 Dukebox SP. Z O.O. A method of manufacturing a solution of nsaid nanoparticles
JPWO2020179701A1 (el) 2019-03-01 2020-09-10
EP4015086A4 (en) * 2019-08-16 2023-09-13 Hiroshima Metal & Machinery Co., Ltd. METHOD FOR PRODUCING ORGANIC NANOPARTICLES AND ORGANIC NANOPARTICLES

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1282405C (en) * 1984-05-21 1991-04-02 Michael R. Violante Method for making uniformly sized particles from water-insoluble organic compounds
IT1227626B (it) * 1988-11-28 1991-04-23 Vectorpharma Int Farmaci supportati aventi velocita' di dissoluzione aumentata e procedimento per la loro preparazione
SE464743B (sv) * 1989-06-21 1991-06-10 Ytkemiska Inst Foerfarande foer framstaellning av laekemedelspartiklar
DK546289D0 (da) * 1989-11-02 1989-11-02 Danochemo As Carotenoidpulvere
IT1243342B (it) * 1990-07-13 1994-06-10 Farcon Ag Composizioni farmaceutiche orali liquide ad attivita' antiinfiammatoria
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles

Also Published As

Publication number Publication date
EP0644755B1 (en) 1997-03-19
AU677783B2 (en) 1997-05-08
JP2009197003A (ja) 2009-09-03
HU9403543D0 (en) 1995-02-28
DK0644755T3 (da) 1997-09-22
WO1993025190A1 (en) 1993-12-23
DE69309056T2 (de) 1997-09-18
JP4439590B2 (ja) 2010-03-24
DE69309056D1 (de) 1997-04-24
CA2118517A1 (en) 1993-12-23
ATE150297T1 (de) 1997-04-15
CA2118517C (en) 2003-10-14
EP0644755A1 (en) 1995-03-29
JPH08501073A (ja) 1996-02-06
HUT70952A (en) 1995-11-28
ES2101323T3 (es) 1997-07-01
AU4396493A (en) 1994-01-04
MX9303452A (es) 1994-01-31

Similar Documents

Publication Publication Date Title
GR3022880T3 (en) Surface modified nsaid nanoparticles.
MY108134A (en) Surface modified drug nanoparticles
AU4900996A (en) Compositions comprising nanoparticles of nsaid
TW281631B (el)
RU93046256A (ru) Противоопухолевые наночастицы с модифицированной поверхностью